NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Someone correct me if I'm wrong, but I believe, Aug 2024 for completion of Phase III. Preliminary phase II (outstanding) results were published in Nature.com pre-print -- awaiting full publication.

Since you asked, ...

First, there is no P3 combo ongoing,

Second, the Aug 24 primary completion is for a different trial, the keytruda combo. And that is just a P1.

Back to the actual combo trial in question,

The trial in the Prin's Nature preprint is the "Poly-ICLC combo" trial. Primary completion is in a few weeks. This is a P2, though with enrollment truncated at N=23 of the planned 60 it is barely that.

The primary results will have updated OS on the 4 lower grade glioma patients that were alive a year ago when the Prins data was snapped, but no new GBM data as they all passed away many years ago (last was 2017). I would not expect them for a year or so. Given the prelim numbers are so close, they might wait for the full study completion and wrap it all up then, ad that will be next year,.

Nothing wrong with the data, but it is very small N. 15 GBM patients, 5 on Poly-ICLC. You can swap a pair of patients and get very different results.